Antimalarial Drugs

• Heme Detoxification Inhibition and Oxidative Stress: Chloroquine and quinine accumulate in the parasitophorous vacuole of infected red blood cells where they bind to heme and prevent its detoxification into hemozoin. Plasmodium parasites digest host hemoglobin within the food vacuole, releasing heme as a toxic byproduct. Chloroquine prevents polymerization of heme into inert hemozoin crystals, causing toxic heme accumulation that generates reactive oxygen species and precipitates parasite death. This mechanism explains chloroquine's efficacy against all Plasmodium species and why resistance emerges through efflux pump mutations (mutations in pfcrt and pfmdr1 genes encoding transporters that actively pump chloroquine from the vacuole). The mechanism is concentration-dependent and primarily targets intraerythrocytic schizonts, though it also inhibits early gametocyte development.

• Antifolate Mechanism - DHFR and DHPS Inhibition: Sulfadoxine-pyrimethamine (SP) and trimethoprim-sulfamethoxazole target dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), enzymes critical for nucleotide synthesis. Pyrimethamine preferentially inhibits parasite DHFR (10,000-fold selectivity over mammalian DHFR), while sulfadoxine inhibits DHPS. This sequential blockade of the folate metabolism pathway prevents tetrahydrofolate synthesis, depleting deoxyribonucleotides and causing parasite DNA synthesis failure. Resistance emerges through point mutations in dhfr and dhps genes that reduce drug binding while preserving enzyme function. SP's slow elimination (half-life 7-9 days) provides extended prophylaxis but means resistant mutations accumulate when used repeatedly in same population.

• Quinone Methide Formation and Mitochondrial Function: Artemisinin and its derivatives (artemether, artesunate, dihydroartemisinin) contain an endoperoxide bridge that generates quinone methides after reduction, particularly by heme iron or other cellular reductants. These reactive intermediates alkylate parasite proteins and inhibit sarco/endoplasmic reticulum calcium ATPase (SERCA), disrupting parasite calcium homeostasis and causing immediate cytostatic effects followed by rapid parasite death. This is the fastest-acting antimalarial, killing parasites within 24-48 hours compared to days for other agents. Artemisinin resistance (reported in Southeast Asia) involves parasite mutations affecting both drug activation and SERCA targeting, reducing parasite susceptibility. The mechanism's rapidity makes artemisinins ideal for severe malaria and high parasitemia states where delayed treatment poses mortality risk.

• Mitochondrial Electron Transport Chain Disruption: Atovaquone-proguanil (primarily atovaquone) inhibits the parasite mitochondrial cytochrome bc1 complex, collapsing the proton gradient and ATP synthesis. This mechanism also disrupts dihydroorotate dehydrogenase, disrupting pyrimidine synthesis. The combination formulation adds proguanil, which acts synergistically through antifolate mechanisms and reduces atovaquone doses needed. Resistance requires multiple mutations and is rare, making this highly effective for drug-resistant strains, particularly P. falciparum.

• Amino Acid Transporter Inhibition: Mefloquine and lumefantrine mechanisms are less precisely defined but involve disruption of parasite amino acid uptake and protein synthesis. Mefloquine's schizonticide activity across all Plasmodium species combined with its long half-life (21 days) provides excellent prophylaxis. Lumefantrine is always paired with artemether (artemisinin derivative) in fixed-dose combinations, where the rapidly-acting artemether quickly clears parasites while lumefantrine's longer half-life (3-4 days) prevents recrudescence.

• Gametocytocidal Effects and Transmission Blocking: Primaquine and pamaquine are 8-aminoquinolines that specifically target mature gametocytes and hypnozoites (dormant liver stage). Primaquine's mechanisms include generating toxic reactive metabolites (via CYP2D6 metabolism to active compounds like primaquine-4-carboxylic acid) that cause oxidative stress. This dual action—treating clinical malaria and preventing transmission—makes primaquine essential for eliminating P. vivax and P. ovale hypnozoites. Crucially, primaquine causes hemolysis in patients with G6PD deficiency, necessitating screening before use. The gametocytocidal effect is crucial for malaria elimination efforts as gametocytes are the stage ingested by mosquitoes.

• **Geographic Location and Plasmodium Species Distribution**: Sub-Saharan Africa is dominated by P. falciparum (90% of cases), the most virulent species with highest mortality risk; Southeast Asia (Thailand, Cambodia, Myanmar) has endemic P. falciparum with significant artemisinin resistance, plus P. vivax and mixed infections; South America maintains P. vivax and P. ovale (requiring primaquine for cure) with limited P. falciparum; Pacific Islands and parts of Asia have P. malariae (typically milder). Returned travelers from different regions require different prophylaxis—chloroquine-sensitive areas (rare now) versus chloroquine-resistant regions (most endemic areas) versus areas with artemisinin-resistant P. falciparum (Thailand border regions). The WHO continuously updates malaria risk maps as resistance patterns evolve.

• **Chloroquine-Resistant Plasmodium falciparum (CRPF)**: Emerged first in Southeast Asia (Cambodia, 1957) and East Africa (1978), now endemic in nearly all malaria-endemic regions except parts of Central America, Caribbean, and certain Pacific islands. Chloroquine resistance is mediated by mutations in pfcrt and pfmdr1 genes encoding efflux transporters that actively pump chloroquine from the parasitophorous vacuole. Geographic variation in resistance mutation prevalence determines whether chloroquine remains viable—absent in Central America and Caribbean, making chloroquine (or hydroxychloroquine) plus proguanil still viable in those regions.

• Artemisinin Resistance: Reported in Southeast Asia (Thai-Cambodian border, Myanmar) since 2008, manifesting as delayed parasite clearance after artemisinin monotherapy. Resistance mutations in parasite KELCH13 gene affect drug activation and downstream effects. This resistance particularly mandates combination therapy (artemisinin + partner drug like lumefantrine) rather than monotherapy to prevent selection of resistant mutants and ensure adequate partner drug levels prevent recrudescence.

• Sulfadoxine-Pyrimethamine (SP) Resistance: High-level resistance in East and Southern Africa and parts of South Asia due to accumulation of dhfr and dhps mutations (quadruple and quintuple mutants common). SP is no longer recommended as treatment in these regions but remains useful for intermittent preventive therapy in pregnancy (IPTp) where drug levels are maintained at protective threshold between exposures.

• Demographic and Host Factors: Pregnancy increases malaria risk and severity (P. falciparum sequestration in placenta), necessitating safe antimalarial prophylaxis—quinine and SP are safer in pregnancy than artemisinin derivatives (though new evidence suggests artemether is safe in second/third trimester). G6PD deficiency prevalence varies by ethnicity (highest in African, Mediterranean, Southeast Asian ancestry), contraindicting primaquine without prior testing. Age (children under 5 and elderly) and immunosuppression (HIV/AIDS) increase severe malaria risk, affecting treatment urgency and drug choice.

• Uncomplicated Malaria - Cyclic Fevers with Symptom-Free Intervals: Classic presentation includes fever spikes every 48 hours (P. vivax, P. ovale, P. malariae - tertian fever) or 72 hours (P. malariae - quartan fever), though P. falciparum fever patterns are often irregular. Patients develop high fevers (often >40°C) followed by drenching diaphoresis and return to baseline temperature, creating apparent wellness between fevers. This cyclicity reflects synchronized parasite schizont rupture releasing merozoites and inflammatory cytokines (IL-1, TNF-α, IL-6). Associated symptoms include severe headache, myalgias, arthralgias, and fatigue. Splenomegaly develops over days due to erythrophagocytosis of infected RBCs and extramedullary hematopoiesis, becoming palpable and tender.

• Severe Malaria Manifestations Requiring Urgent Treatment: Cerebral malaria (impaired consciousness/coma in P. falciparum infection) results from parasite sequestration in brain vasculature causing microvascular obstruction and blood-brain barrier disruption; requires immediate IV artesunate (superior to quinine based on AQUAMAT trial). Acute kidney injury develops from acute tubular necrosis secondary to hypovolemia, hemolysis (from parasitized RBC rupture), and direct toxic effects; presentation includes oliguria, rising creatinine, hyperkalemia. Severe anemia (hemoglobin <7 g/dL) results from destruction of both infected and uninfected RBCs (due to altered deformability and complement deposition). Pulmonary edema/ARDS develops from increased vascular permeability and cytokine release; presents as dyspnea, hypoxia, pulmonary infiltrates. Hypoglycemia (blood glucose <40 mg/dL) occurs from both parasite consumption of glucose and impaired hepatic gluconeogenesis; presents with altered mental status that may be mistaken for cerebral malaria alone. Lactic acidosis develops from anaerobic metabolism and organ hypoperfusion.

• Physical Examination Findings: Jaundice appears from hemolysis and hepatic dysfunction (indirect hyperbilirubinemia predominates). Splenomegaly (present in >50% of malaria cases) typically mild to moderate; massive splenomegaly suggests chronic malaria or other diagnoses. Hepatomegaly from portal blood pooling and hepatocyte inflammation. Fundoscopic exam in cerebral malaria may show retinal whitening (cotton-wool spots), retinal hemorrhages, and papilledema. Impaired consciousness with coma in severe malaria; seizures (especially in children) from cerebral edema and metabolic disturbances.

• Clinical Variants by Species: P. falciparum is most virulent, most likely to progress to severe malaria (cerebral, renal, pulmonary complications) within 3-5 days if untreated; highest mortality (1-2% in adults, higher in children and pregnant women if untreated). P. vivax and P. ovale typically milder but require primaquine to cure hypnozoites (otherwise relapses occur over weeks-months if untreated). P. malariae causes chronic low-grade parasitemia potentially lasting years; typically mild but can cause nephrotic syndrome from immune complex deposition (diffuse proliferative glomerulonephritis). Asymptomatic parasitemia occurs in semi-immune individuals in endemic areas.

• Thick and Thin Blood Smears (Gold Standard for Rapid Diagnosis): Thick smears (without RBC lysis) detect parasites through concentration; thin smears (with RBC lysis) identify species and quantify parasitemia percentage. Sensitivity approaches 95% if ≥5 smears examined when parasitemia >1%; sensitivity drops significantly at <0.1% parasitemia. Smears should be examined within 1-2 hours as morphology degrades; Giemsa or Wright-Giemsa staining required. Interpretation requires trained microscopist identifying ring forms (young trophozoites, earliest visible stage), mature trophozoites, schizonts (immature and mature), and gametocytes. P. falciparum presents with multiple RBCs infected simultaneously (indicating high virulence potential), presence of gametocytes even early in illness (facilitating transmission), and RBC size unaffected. P. vivax and P. ovale cause RBC enlargement and distortion. Rapid diagnostic tests (RDTs) using immunochromatography detect HRP2 antigen (P. falciparum-specific) or pan-malarial antigens; sensitivity >95% at parasitemia >100/μL but lower at submicroscopic levels.

• Quantitative PCR (qPCR) - Gold Standard for Species Identification and Low-Level Detection: Detects parasite DNA with sensitivity to <1 parasite/μL; identifies species definitively when microscopy uncertain (especially detecting mixed infections). qPCR increasingly used for surveillance and research; not practical for emergency diagnosis but crucial for confirming resistance-associated mutations if needed. In clinical practice, used in reference labs to confirm species when microscopy inconclusive or to detect submicroscopic parasitemia in elimination settings.

• Complete Blood Count Abnormalities: Anemia (hemoglobin often 7-10 g/dL in severe malaria) from RBC destruction and bone marrow suppression. Thrombocytopenia (platelets often <100,000/μL, sometimes <50,000) is nearly universal in malaria; severe thrombocytopenia (<20,000) rare but indicates severe disease. Leukopenia (WBC <4,000) common in P. falciparum, fewer WBCs in P. vivax. High reticulocyte count reflects compensatory RBC production.

• Biochemical Markers of Severity: Creatinine elevation (>3 mg/dL indicates AKI requiring aggressive supportive care and possible dialysis). Hypoglycemia (<40 mg/dL) indicates severe metabolic disturbance and mortality risk; must be corrected immediately with IV dextrose. Elevated bilirubin (predominantly indirect from hemolysis, typically <4 mg/dL in uncomplicated malaria; >3 mg/dL suggests severe disease). Elevated LDH (>1000 IU/L) indicates hemolysis and tissue damage; LDH/AST ratio >1 suggests malaria over viral hepatitis. Metabolic acidosis (low HCO3, low pH) indicates severe malaria; lactate elevation confirms lactic acidosis (poor prognostic sign).

• Diagnostic Criteria for Severe Malaria (WHO): Impaired consciousness (GCS <11 or coma), severe normocytic anemia (hemoglobin <7 g/dL), renal impairment (creatinine >3 mg/dL or oliguria), pulmonary edema or ARDS, hypoglycemia (<40 mg/dL), hyperlactatemia (lactate >5 mmol/L), metabolic acidosis (HCO3 <15 mmol/L), bleeding/coagulopathy (prolonged PT/INR, low platelets with bleeding), jaundice + abnormal LFTs, parasite density >30% on blood smear. Meeting any criterion warrants severe malaria management with IV artesunate.

• Differential Diagnosis: Bacterial sepsis (similar fever and shock but different smear findings), dengue fever (rash, platelet thrombosis

4-Aminoquinolines (chloroquine, hydroxychloroquine)

• Retinopathy: cumulative-dose–dependent drug binding to melanin in the retinal pigment epithelium produces the classic bull's-eye maculopathy, which may progress after the drug is stopped. The American Academy of Ophthalmology recommends a baseline exam and annual screening (visual fields plus spectral-domain OCT) after roughly five years of use, with risk driven by weight-based daily dose, duration, renal impairment, and concurrent tamoxifen.
• Cardiotoxicity: QT prolongation and, with chronic high-dose use, a restrictive/hypertrophic cardiomyopathy with conduction block. Acute overdose causes sodium-channel blockade with wide QRS, refractory hypotension, and hypokalemia; per toxicology/poison-center practice (not a formal CDC or WHO recommendation), management is high-dose diazepam plus epinephrine, with sodium bicarbonate for QRS widening — consult poison control early.
• Other: intense pruritus (especially in patients of African descent), and exacerbation of psoriasis and porphyria cutanea tarda.

Quinine/quinidine

• Cinchonism: tinnitus, high-tone hearing loss, headache, nausea, blurred vision — dose-related and usually reversible.
• Hyperinsulinemic hypoglycemia: direct pancreatic beta-cell stimulation; check glucose in any obtunded treated patient before assuming worsening cerebral malaria.
• Immune-mediated cytopenias: quinine-dependent antibodies cause abrupt thrombocytopenia and can trigger TTP/HUS; also QT/QRS prolongation (quinidine-like class Ia effect).

8-Aminoquinolines (primaquine, tafenoquine)

• Oxidant hemolysis in G6PD deficiency and methemoglobinemia (worse in NADH-methemoglobin reductase deficiency). Quantitative G6PD testing is mandatory before use (CDC). Both are contraindicated in pregnancy because fetal G6PD status is unknown. Methylene blue treats methemoglobinemia but is itself contraindicated in G6PD deficiency.

Others

• Mefloquine: FDA boxed warning for neuropsychiatric toxicity — vivid dreams, anxiety, psychosis, seizures; avoid with seizure disorder, active psychiatric illness, or cardiac conduction disease.
• Artemisinins: post-artesunate delayed hemolysis 1–3 weeks after therapy; CDC advises follow-up hemoglobin monitoring for about 4 weeks.
• Sulfadoxine-pyrimethamine: Stevens-Johnson syndrome/TEN and megaloblastic marrow suppression, rescued with folinic acid (leucovorin), not folic acid.
• Atovaquone-proguanil: GI upset and transaminitis; avoid in severe renal impairment. Doxycycline: photosensitivity, pill esophagitis; avoid in pregnancy and children under 8.

• IV artesunate is first-line for severe malaria in the United States (CDC), having replaced quinidine gluconate, which is no longer marketed. The single best next step for any patient meeting a severe-malaria criterion is IV artesunate plus a full oral follow-on regimen (artemether-lumefantrine preferred; alternatives are atovaquone-proguanil, quinine sulfate plus doxycycline or clindamycin, or mefloquine) — never artesunate alone, since its very short half-life means high recrudescence rates without a full-course partner regimen (and monotherapy also drives *kelch13*-mediated resistance).
• Check G6PD before primaquine or tafenoquine. This is the most-tested single next step in a P. vivax or P. ovale stem. Radical cure of hypnozoites is what prevents relapse; chloroquine or an ACT alone clears the blood stage only, and the patient relapses weeks to months later.
• Bull's-eye maculopathy is the chloroquine/hydroxychloroquine buzzword; cinchonism (tinnitus, headache, blurred vision) is the quinine buzzword. Do not swap them.
• Altered mental status in a patient on quinine is hypoglycemia until proven otherwise — quinine stimulates insulin release. Check a fingerstick glucose before escalating for presumed cerebral malaria.
• Mefloquine's neuropsychiatric boxed warning is the association examiners test. A traveler with a seizure disorder, depression, or psychosis should receive atovaquone-proguanil or doxycycline instead.
• Chemoprophylaxis timing distinguishes the agents: atovaquone-proguanil and primaquine (causal prophylactics, active against liver stages) start 1–2 days before travel and continue 7 days after departure; doxycycline starts 1–2 days before travel but must continue 4 weeks after departure, because it is a blood-stage schizonticide without causal activity; chloroquine starts 1–2 weeks before and mefloquine at least 2 weeks before, both continued 4 weeks after departure (CDC Yellow Book).
• **Common distractor — chloroquine for African P. falciparum.** Chloroquine remains appropriate only in the few documented chloroquine-sensitive areas (for example Haiti and parts of Central America north/west of the Panama Canal); elsewhere assume resistance.
• Pregnancy: doxycycline, primaquine, and tafenoquine are contraindicated; CDC lists mefloquine as the prophylaxis option for chloroquine-resistant areas, and artesunate is still given for severe malaria in pregnancy because untreated disease is lethal.